Archive


Category: Apretude

  • FDA okays ViiV’s Apretude as first injectable for HIV PrEP

    GlaxoSmithKline’ majority-owned HIV unit ViiV has scored a key FDA approval, getting approval for its long-acting drug cabotegravir as the first injectable for pre-exposure prophylaxis (PrEP) –challenging market leader Gilead Sciences. Cabotegravir – given the trade name Apretude – can be dosed just six times a year and showed superior results to daily, oral therapy […]